Beam Therapeutics announced today that it has launched with $87 million in Series A funding to develop precision genetic medicines that make edits to individual base pairs in the genome.
HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and biotech friend Takeda, to work on antibody therapies for various gastrointestinal diseases, cancers and other disorders.
Shares of Boston-based resTORbio (NASDAQ: TORC) have nearly doubled to roughly $16 apiece, based on positive results the company released this morning from a Phase 2b trial of its drug for respiratory tract infections.
-Platelet BioGenesis (PBG), the leader in the production of functional human platelets (PLTs+™) from stem cells and the development of platelet-based therapeutics, announced it has moved into brand new lab space in Cambridge, MA. Located next to MIT, the newly renovated property puts Platelet BioGenesis in the heart of the most dynamic biotech cluster in the world.
Founded by a who’s who of researchers, including Massachusetts Institute of Technology professors Timothy Lu and Jim Collins; Mayo Clinic Assistant professor Hu Li; and University of California San Diego assistant professor, Prashant Mali, Engine is leveraging experts in synthetic biology and drug discovery to create a new way to build and test novel medicines.
Computer science and engineering, meet drug R&D. MIT star Timothy Lu intertwines technologies for an offbeat biotech launch
At 37, Timothy Lu’s life and work has already spanned several scientific disciplines and cultures. He’s lived in Asia and the US, and after gathering degrees in electrical engineering and computer science at MIT, he struck out to pick up his medical degree at Harvard Med and then a PhD at the Harvard-MIT Health Sciences and Technology Medical Engineering and Medical Physics Program.
HiFiBiO Therapeutics has completed a $37.5 million series B funding round, with plans to advance its antibody pipeline in oncology and autoimmune research after expanding its leadership team last summer.
Recent FDA approvals have validated the use of chimeric antigen receptor T cells (CAR-Ts) to fight blood cancers, but the technology is still far from perfect. Researchers working on CAR-T therapies have run into problems with patient relapse, toxicity and specificity, and not all patients respond well. Wilson Wong and his team at Boston University have devised what they call the "Swiss army knife" of CAR-T to address these issues.
Scientists in China have used a next-generation form of CRISPR genome-editing to repair a disease-causing mutation in human embryos, the first use of the technique in viable embryos that were created by a standard fertility clinic technique.
Cambridge, Massachusetts-based Platelet Biogenesis (PBG) was awarded a two-year, $3.5 million grant from the U.S. Department of Defense (DoD). The funds are to support the company’s proprietary bioreactor to produce therapeutic amounts of platelets.